NASDAQ:ALMS Alumis (ALMS) Stock Price, News & Analysis $5.14 -0.46 (-8.21%) Closing price 04:00 PM EasternExtended Trading$5.10 -0.04 (-0.86%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Alumis Stock (NASDAQ:ALMS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alumis alerts:Sign Up Key Stats Today's Range$5.00▼$5.8050-Day Range$5.14▼$10.5852-Week Range$5.00▼$31.35Volume2.20 million shsAverage Volume1.84 million shsMarket Capitalization$665.27 millionP/E RatioN/ADividend YieldN/APrice Target$31.27Consensus RatingModerate Buy Company Overview Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use. Alumis was formed in 2024 through the combination of Esker Therapeutics and Kintara Therapeutics and is based in South San Francisco, California. Its work includes conducting clinical trials and developing potential treatments for patients with inflammatory and autoimmune conditions.AI Generated. May Contain Errors. Read More Alumis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreALMS MarketRank™: 3.872020242375 of 5 starsAlumis scored higher than 77% of companies evaluated by MarketBeat, and ranked 103rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAlumis has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAlumis has a consensus price target of $31.27, representing about 508.4% upside from its current price of $5.14.Amount of Analyst CoverageAlumis has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alumis' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alumis are expected to grow in the coming year, from ($2.95) to ($2.84) per share.Price to Book Value per Share RatioAlumis has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.86% of the float of Alumis has been sold short.Short Interest Ratio / Days to CoverAlumis has a short interest ratio ("days to cover") of 5.78.Change versus previous monthShort interest in Alumis has recently decreased by 0.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlumis does not currently pay a dividend.Dividend GrowthAlumis does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.14 News SentimentAlumis has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Alumis this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for ALMS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat Follows3 people have added Alumis to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $9,688,716.00 in company stock, which represents 1.4564% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Alumis insiders have bought 933.58% more of their company's stock than they have sold. Specifically, they have bought $10,726,520.00 in company stock and sold $1,037,804.00 in company stock.Percentage Held by Insiders33.70% of the stock of Alumis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAlumis has minimal institutional ownership at this time.Read more about Alumis' insider trading history. Receive ALMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alumis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALMS Stock News HeadlinesOppenheimer Adjusts Alumis Price Target to $28 From $37, Maintains Outperform RatingNovember 16 at 6:16 PM | marketscreener.comMAlumis' Path Narrows Amid Promising Profile, Oppenheimer SaysNovember 16 at 6:16 PM | marketscreener.comMYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 16 at 1:00 AM | Profits Run (Ad)Alumis (ALMS) Stock Fair Value Moves Lower After Mixed Analyst Views On LUMUSNovember 16 at 8:11 AM | finance.yahoo.comAlumis (NASDAQ:ALMS) Stock Gets Price Target Reduction from Wells Fargo & CompanyNovember 16 at 2:37 AM | americanbankingnews.comAlumis (NASDAQ:ALMS) Stock Gets Price Target Reduction from HC WainwrightNovember 16 at 1:36 AM | americanbankingnews.comAlumis (NASDAQ:ALMS) Shares Down 9.4% Following Analyst DowngradeNovember 15 at 10:18 AM | americanbankingnews.comAlumis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12, 2026 | marketscreener.comMSee More Headlines ALMS Stock Analysis - Frequently Asked Questions How have ALMS shares performed this year? Alumis' stock was trading at $9.76 at the beginning of the year. Since then, ALMS stock has decreased by 47.3% and is now trading at $5.14. How were Alumis' earnings last quarter? Alumis Inc. (NASDAQ:ALMS) posted its earnings results on Thursday, November, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.03. The business earned $1.91 million during the quarter, compared to the consensus estimate of $1.90 million. Alumis had a negative net margin of 5,844.54% and a negative trailing twelve-month return on equity of 86.62%. When did Alumis IPO? Alumis (ALMS) raised $210 million in an initial public offering on Friday, June 28th 2024. The company issued 13,125,000 shares at $16.00 per share. Who are Alumis' major shareholders? Top institutional investors of Alumis include State Street Corp (2.28%), Marshall Wace LLP (0.82%), Pictet Asset Management Holding SA (0.50%) and First Trust Advisors LP (0.25%). Insiders that own company stock include James B Tananbaum, Foresite Labs, Llc, Foresite Capital Management Vi, Srinivas Akkaraju, Roy C Hardiman, Martin Babler, Jorn Drappa, Mark Christopher Bradley, David M Goldstein, John R Schroer, Alan Colowick and Sanam Pangali. View institutional ownership trends. How do I buy shares of Alumis? Shares of ALMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alumis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alumis investors own include NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), Intel (INTC), Advanced Micro Devices (AMD), SoundHound AI (SOUN) and Arista Networks (ANET). Company Calendar Last Earnings11/12/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ALMS's financial health is in the Red zone, according to TradeSmith. ALMS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALMS Previous SymbolNASDAQ:ALMS CIK1847367 Webwww.alumis.com Phone(650) 231-6625FaxN/AEmployees239Year Founded2021Price Target and Rating Average Price Target for Alumis$31.27 High Price Target$46.00 Low Price Target$9.00 Potential Upside/Downside+508.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$243.32 million Net Margins-5,844.54% Pretax Margin-5,957.21% Return on Equity-86.62% Return on Assets-69.57% Debt Debt-to-Equity RatioN/A Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$24.05 million Price / Sales27.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book1.78Miscellaneous Outstanding Shares129,430,000Free Float85,815,000Market Cap$665.27 million OptionableOptionable Beta-0.28 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:ALMS) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredSmall-Cap SMX is Taking its Technology into Multiple Trillion-Dollar Industries!SMX (NASDAQ: SMX) uses proprietary molecular-marking technology and a Digital Material Passport platform to gi...Smallcaps Daily | SponsoredThis Tech Could Be Bigger Than Apple, Amazon, and Microsoft CombinedA breakthrough technology backed by Elon Musk, Sam Altman and Jensen Huang could one day be worth more than Ap...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.